« Back
Home /
Parkin ELISA Kits (PARK2; human, mouse, rat, canine) 96T

Parkin ELISA Kits (PARK2; human, mouse, rat, canine) 96T

Manufacturer	Fivephoton
Category	Oncology Neuroscience Neuroinflammation Neural Mitochondrial Function Protein Aggregation, Clearance & Misfolding By Cell Type Carcinoma Hematology Myeloma Cell Biology Cell Status ELISA Autophagy ELISA & Immunoassays ELISA Kits Immunoassay By Organ Heart & Blood Cancer
Type	Elisa-Kit
Specific against	Human, Mouse, Rat, Canine
Amount	96T
Item no.	Prk-ELISA
Targets	AURKB;;PRKN
eClass 6.1	32160605
eClass 9.0	32160605
Available
Poisonous Material	Sodium Azide (0.1%)
Highlights	Fully pre-configured sandwich ELISA format providing convenience, and optimal selectivity and sensitivity. Affinity purified polyclonal capture antibody coated on plate. Separate HRP-conjugated detection antibody. Colorimetric detection at 450 nM Rapid assay format. Total incubation time at 37C is 1 hr.
Background	The included ELISA 96-well micro-strip plate is provided pre-coated with an affinity purified rabbit polyclonal antibody selective to the antigen. Upon addition of samples to the wells, the antigen in solution binds to the antibody and becomes indirectly linked to the solid support. After washes of unbound materials, a second affinity purified polyclonal antibody conjugated with horse-radish peroxidase (HRP) is added, followed by a second incubation period. Unbound antibody is washed, and then color reagents are added, which upon conversion by HRP, become blue colored. A stop solution is added to block further reaction between HRP and the colorimetric substrates, converting the solution into a yellow coloration. An absorbance multiplate reader is used to quantitate the colorimetric reaction at 450 nm. This assay requires approximately 1.5 hrs to complete at 37C.
References	Xabier Agirre, et.al. (2006). Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia. International journal of cancer Journal international du cancer 118 (8) p. 1945-1953. Nonmotor Symptoms in Patients with PARK2 MutationsAsako Yoritaka, Yumi Shimo, Yasushi Shimo, Yuichi Inoue, Hiroyo Yoshino, Nobutaka Hattori (2011). Parkinsons disease 2011 p. 47364. George Poulogiannis, Rebecca E McIntyre, Maria Dimitriadi, John R Apps, Catherine H Wilson, Koichi Ichimura, Feijun Luo, Lewis C Cantley, Andrew H Wyllie, David J Adams, Mark J Arends (2010). PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proceedings of the National Academy of Sciences of the United States of America 107 (34) p. 15145-15150. Yasuhiro Yamamura (2007). The long journey to the discovery of PARK2. Rinsho shinkeigaku Clinical neurology 47 (11) p. 749-751.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 96T

available

Delivery expected until 6/6/2024